Two different dosing regimens demonstrated efficacy with one showing a better profile. No hospitalisations or severe cases of COVID-19 in participants treated with AZD1222. Positive high-level results from an interim analysis of clinical trials of AZD1222 in the UK and Brazil showed the vaccine was highly effective in preventing COVID-19, the primary endpoint, and no …
Continue reading “AZD1222 vaccine met primary efficacy endpoint in preventing COVID-19”